A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)

Inclusion Criteria:

1. Participant has given written informed consent to participate in the study inaccordance with local regulations

2. Adult male and female participants ≥18 years of age at the Screening Visit

3. Body mass index ≥18.0 to ≤40.0 kilogram per meter square (kg/m^2) at Screening

4. Diagnosis of type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) withchronic DPNP, at Screening

5. Pain from DPNP present for at least 6 months prior to Screening

6. At the Screening Visit, glycosylated hemoglobin (A1C) must be ≤11%.

7. Stable regimen for the treatment of T1DM or T2DM for ≥3 months prior to Screening

8. Willing to adhere to the prohibitions and restrictions specified in the protocol.

Exclusion Criteria:

1. Presence of other painful conditions that may confound assessment or self-evaluationof DPNP

2. History of neurolytic or neurosurgical therapy for DPNP

3. Use of opioid medications for management of DPNP within the 2 months prior to theScreening Visit.

4. Use of prescription topical analgesics (eg, capsaicin) indicated for neuropathicpain within 3 months prior to Screening

5. Use of nonsteroidal anti-inflammatory drugs (NSAIDs) less than 2 weeks prior toScreening